Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Linear scleroderma in children

L E Eubanks1, E I McBurney, W Galen

  • 1Department of Dermatology, Tulane University School of Medicine, New Orleans, Louisiana, USA.

International Journal of Dermatology
|May 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation of Charmonium Sequential Suppression in Heavy-Ion Collisions at the Relativistic Heavy Ion Collider.

Physical review letters·2026
Same author

Reirradiation Options for Previously Irradiated Prostate Cancer: Is It Feasible to Randomise Between Treatment With Stereotactic Body Radiotherapy (SBRT) Versus High-Dose-Rate Brachytherapy?

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Energy Independence of the Collins Asymmetry in p^{↑}p Collisions.

Physical review letters·2026
Same author

Precision Measurement of Net-Proton-Number Fluctuations in Au+Au Collisions at RHIC.

Physical review letters·2025
Same author

Onset of Constituent Quark Number Scaling in Heavy-Ion Collisions at RHIC.

Physical review letters·2025
Same author

Measurement of In-Medium Jet Modification Using Direct Photon+Jet and π^{0}+Jet Correlations in p+p and Central Au+Au Collisions at sqrt[s_{NN}]=200  GeV.

Physical review letters·2025
Same journal

SENTINOLD and the Challenge of Meaningful Risk Prediction in Melanoma.

International journal of dermatology·2026
Same journal

The "Stamp-n-Tack" Technique: An Ink-Guided Precision Method for Anchoring Tissue After Releasing Facial Retaining Ligaments in Large Facial Flap Reconstruction.

International journal of dermatology·2026
Same journal

Counterfactual Dermatology With Generative Models.

International journal of dermatology·2026
Same journal

Correlation of Clinical and Histopathological Features With Anti-Desmoglein Antibody Profile in Pemphigus Patients.

International journal of dermatology·2026
Same journal

Paracetamol-Induced Generalized Bullous Fixed Drug Eruption With Positive Anti-BP230 Antibody and Confirmed With Oral Provocation Test in a Child: A Case Report From the Philippines.

International journal of dermatology·2026
Same journal

Clinicopathological Challenge: A Painful Violaceous Reticulated Patch.

International journal of dermatology·2026
See all related articles

Linear scleroderma is a rare skin condition affecting children, presenting as band-like lesions. Current treatments are inconsistent, but new therapies like diphenylhydantoin warrant clinical trials.

Area of Science:

  • Dermatology
  • Pediatrics
  • Rheumatology

Background:

  • Linear scleroderma is a rare cutaneous condition of unknown origin.
  • It primarily affects children, manifesting as asymmetric, band-like lesions.
  • This review covers diagnosis, pathogenesis, and treatment of linear scleroderma.

Observation:

  • Six pediatric cases of linear scleroderma are presented, aged 6-17 years.
  • Five of the six patients were girls.
  • One patient presented with the 'en coup de sabre' subtype.

Findings:

  • Linear scleroderma is diagnosed clinically.
  • Etiology and pathogenesis remain undetermined.
  • No single treatment has proven consistently effective.

Related Experiment Videos

Implications:

  • Further research into the pathogenesis of linear scleroderma is needed.
  • Diphenylhydantoin and ticlopidine hydrochloride show potential therapeutic value.
  • Clinical trials are recommended to evaluate novel treatment options for linear scleroderma.